Investor Presentation
Released
Released
Announcement PDF
Alterity Therapeutics
(NASDAQ:ATHE, ASX:ATH)
David Stamler, MD
CEO
November 2023
Forward Looking Statements
This presentation may contain some statements that
may be considered “Forward-Looking Statements”,
within the meaning of the US Securities Laws. Thus,
any forward-looking statement relating to financial
projections or other statements relating to the
Company’s plans, objectives, expectations or intentions
involve risks and uncertainties that may cause actual
results to differ materially. For a discussion of such
risks and uncertainties as they relate to us, please refer
to our 2023 Form 20-F, filed with US Securities and
Exchange Commission, in particular Item 3, Section D,
titled “Risk Factors.’’
2
Alterity is dedicated to
creating an alternate
future for people living
with neurodegenerative
diseases.
Alterity means the state of
being different
Our goal is to modify the
course of disease
We’re here to disrupt the
trajectory of illness and
improve quality of life
3
Investment Highlights
• Developing disease modifying therapies
• ATH434: Novel drug candidate targeting proteins implicated in neurodegeneration of
Parkinson’s disease and related disorders
• First indication: Multiple System Atrophy (MSA), a parkinsonian disorder with no
approved treatment
•
Orphan Drug designation for MSA in the US and EU
•
Phase 2 program ongoing
•
Randomized, double blind study in early-stage MSA
•
Biomarker trial in more advanced MSA
• Strong patent portfolio
• Significant R&D experience including 3 neurology drug approvals by FDA
4
Experienced Leadership Team with Multiple
FDA Approvals in Neurology
David Stamler, M.D.
Kathryn Andrews, CPA
Chief Executive Officer
Chief Financial Officer
Auspex/Teva | Abbott | Prestwick
Xenoport | Fujisawa
Antisense Therapeutics | Rio Tinto |
Consultant
• 3 FDA Approvals in Neurology
• Former CMO, Auspex
• VP, Clinical Development &
Therapeutic Head, Movement
Disorders, Teva Pharmaceuticals
• Part of Teva’s US$3.5 billion
acquisition of Auspex in 2015
• Extensive experience advising
Margaret Bradbury, Ph.D.
Cynthia Wong, M.P.H.
VP, Nonclinical Development
Senior Director, Clinical Operations
Auspex/Teva | Neurocrine | Merck
Auspex/Teva | Nextwave | Astex |
Intermune | Impax Labs
• Auspex - led strategic planning and
private and public CFOs, mainly in
the biotechnology sector
program management in
Huntington Disease chorea from
IND through NDA filing
• Prior CFO and Company Secretary
• Teva - led non-clinical development
of Antisense Therapeutics Limited
• 15+ years in finance and accounting
roles at Rio Tinto Limited and BP
Australia Limited
of several neuroscience programs
• Clinical Operations leadership at
Auspex/Teva.
• Led clinical trial activities for the
registration study of AUSTEDO® in
Huntington Disease chorea.
• Prior, led Phase 1-3 studies,
including registration studies for
marketing approval for Quillichew
ER, Esbriet and Infergen.
• Led development of AUSTEDO®
(deutetrabenazine) for treatment
of Huntington disease and Tardive
dyskinesia, both approved in
2017
5
Parkinsonian Disorders: A Significant Unmet Need
• Parkinsonism is a syndrome of motor symptoms that
includes slowed movement, stiffness and tremor
•
Parkinson’s disease most common cause
•
Major source of disability
• Parkinsonian disorders include Multiple system atrophy
(MSA) and Progressive supranuclear palsy (PSP)
•
Prominent non-motor symptoms
•
Limited response to available treatments
Current therapies treat the symptoms and NOT
the underlying pathology of disease
PARKINSONIAN DISORDERS
MSA
PARKINSON’S
DISEASE
PSP
6
Promising Portfolio in Neurodegenerative Diseases
ASSET
PROGRAM
INDICATION
ATH434-201
Multiple System Atrophy
Early Stage
ATH434-202
Multiple System Atrophy
Advanced
bioMUSE
Multiple System Atrophy
Natural History Study
ATH434
Parkinson’s Disease
Drug
Discovery
Neurodegenerative
Diseases
PHASE
DISCOVERY
PRECLINICAL
NATURAL
HISTORY
PARTNER
PHASE 1
PHASE 2
PARTNER /
COLLABORATOR
7
The Role of Alpha-Synuclein and Iron
in Parkinsonian Disorders
8
Alpha-Synuclein: Critical for Normal Neuron
Function
Our Strategy
• Inhibit misfolding and aggregation of intracellular
α‐synuclein
• Target misfolding α-synuclein by redistributing loosely
bound excess iron in areas of pathology
• Address underlying pathology of disease
α-Synuclein
Health
Disease
• An intracellular protein critical for normal function of neurons
• Native, unfolded protein enables neurotransmission
• α-synuclein aggregates in Parkinson’s Disease and Multiple
System Atrophy
Sources: Ritchie et al, 2012; DOI:10.4236/health.2012.431175; Bengoa-Vergniory et al, 2017.DOI 10.1007/s00401-017-1755-1
9
Increased Brain Iron in Synuclein-related Diseases
Multiple System Atrophy
Parkinson’s disease
Substantia nigra (T)
n=7
n=9
Substantia nigra (pc)
n=8
n=3
Patients
*
Healthy
*
n = 13
Cerebellum
n = 24
0
10000
20000
30000
nmol iron/g of human brain
Control
n=8
n = 11
Caudate nucleus
n=8
n = 10
Putamen (M)
n=8
n = 10
Putamen (L)
n=8
n=8
Globus pallidus (M)
n=8
n=9
Globus pallidus (L)
n=8
n = 11
Substantia nigra (T)
n=6
n=9
Cerebellum
n=8
n = 12
Dexter et al. Brain.1991
Advanced Quantitative MRI to measure brain iron
MSA
Cerebral cortex
0
*
*
*
*
10000
20000
30000
nmol iron/g of human brain
Courtesy of P. Trujillo, D. Claassen
10
Iron: Critical in Disease Pathogenesis
α-Synuclein and iron are strong contributors to
the pathology of MSA
Oxidative Stress
• Adverse impact of excess loosely bound iron
•
Promotes α-synuclein aggregation
•
Root cause of oxidative stress which damages
intracellular structures and leads to neuroinflammation
• Hallmark of MSA pathology
•
Neuron loss in multiple brain regions
•
Glial cytoplasmic inclusions (GCI)
Sources: Kaindlstorfer, J. Alzheimers Dis. 2018; Rodgers, J Neural Transm (Vienna). 2011
Neuroinflammation
Iron Imbalance
11
Approach: Address Underlying Pathology
of Disease
Redistribute excess iron
in the Central Nervous System
Reduce α‐synuclein
aggregation
and
Oxidative stress
Rescue neuronal
function
Potential Disease Modifying Therapy for MSA
12
ATH434: Disease Modifying Drug
Candidate
13
ATH434: Potential Use in Multiple Indications
• Small molecule drug candidate that reduces α-synuclein aggregation
•
Iron chaperone, redistributes loosely bound excess iron in brain
•
Oral agent (tablet) for ease of use
•
Readily absorbed, shown to reach site of action in man
• Potential to treat various Parkinsonian disorders
ATH434
• Orphan Drug Designation in the US and EU for the treatment of MSA
• Development pathway endorsed by FDA and EMA
14
Pharmacologic Actions of ATH434only
Redistributes loosely bound
excess iron
***
10000
***
60
5000
0
0
1
10
ATH434 (µM)
Blocks increase
in brain iron
20
Fe (mg/kg)
Fe released (CPM)
15000
Reduces
α‐synuclein
aggregation
40
20
0
Kd for Fe3+
10-5
ATH434
10-10
Transferrin
10-23
Stronger
binding
α-synuclein
UL
VEH
ATH434
400
ATH434 does not interfere with normal iron
trafficking proteins
Inhibits oxidative
stress in vivo
8-Isoprostane (% UL)
Ligand
*
**
300
200
0
Sources: Davies et al, 2011; Finkelstein, et al, 2017; Harris WR, 2002.
* P < 0.05, ** P < 0.01, *** P < 0.001
*
100
VEH
ATH434
15
ATH434 Reduces Alpha-Synuclein-related Neuropathology
in Parkinson’s Disease Animal Models
↓ α-Synuclein
**
hA53T α-syn
4
2
0
Vehicle
0
*
**
UL
VEH
ATH434
Total SNpc neurons
α-syn (OD)
0
W/T
Vehicle
ATH434
6000
2
1
4000
ATH434
3
MPTP
Mouse
**
8000
Total SNpc neurons
6
hA53T
Mouse
Preserves Neurons
*
3000
0
0
1
3
** ***
***
10 30 80
C
ATH434 (mg/kg)
Sources: Finkelstein, et al. Acta Neuropath Comm. 2017 | TG: transgenic, W/T: wild type, UL: unlesioned, C: control |* P < 0.05, ** P < 0.01, *** P < 0.001
16
ATH434 Reduces Alpha-Synuclein-related Neuropathology
and Improves Motor Function in MSA Animal Model
0.6
0.4
0.2
0.0
Vehicle
ATH434
6000
**
**
**
4000
2000
Iron in SN
WT
0
***
4000
Number of GCI
Relative to Total Protein
Exp. #1
Total SNpc neurons
**
0.8
Glial inclusions
SN neurons
α-Synuclein
3
10
***
***
3000
2000
1000
0
30
0
3
10
30
ATH434 (mg/kg)
ATH434 (mg/kg)
Striatal neurons
Motor Function
0.06
non-treated
slips/step
Exp. #2
ATH434
0.04
*
0.02
0.00
6
8
10
12
age (months)
Sources: Finkelstein, et al. J. Parkinson’s Disease 2022 | Heras-Garvin, et al. Mov. Disorders 2021
* P < 0.05, ** P < 0.01, *** P < 0.001
17
Multiple System Atrophy
Clinical Development Program
18
Multiple System Atrophy (MSA) is a Rare, Highly Debilitating
and Rapidly Progressive Neurodegenerative Disorder
• Clinical impairments include
•
Motor: Parkinsonism, uncoordinated movements,
balance problems/falls
•
Autonomic dysfunction: Reduced ability to
maintain blood pressure, control bladder and
bowel function
• 60% require use of wheelchair within 5 years
• Median survival 7.5 years after symptom onset
Death can occur
Clinically Established MSA
Premotor MSA
• Excess brain iron correlates with disease severity
Sources: Fanciulli, Wenning. NEJM 2015 | Wenning, et al. Mov Disorders 2022 | Coon, et al. Brain 2015 | Claassen,et al. Mov Disorders 2021
Clinically Probable MSA
0
3
Years
6
9
19
Phase 1: ATH434 Well-Tolerated with
No Serious Adverse Events
• No SAEs or AEs leading to withdrawal
• All AEs were mild to moderate in severity
• Most common AE reported was headache
ΔΔQTcF (msec)
No evidence of QT prolongation
• Similar AE profile for adults and older
adults
• Favorable cardiovascular safety profile
Source: Phase 1 clinical trial; Alterity data on file
No effect on BP with Standing
SBP (mmHg) Standing - Supine
• No significant findings observed in vital
signs, clinical labs or 12-lead ECGs
Concentration (ng/mL)
20
10
Placebo
100 mg bid
0
200 mg bid
250 mg bid
-10
250 mg bid >65
-20
20
Phase 1: Achieved Drug Concentrations Associated
with Efficacy in Animal Models
ATH434 in plasma (ng/mL)
10000
Plasma and CSF Levels at Steady-State
Plasma (unbound, ng/mL)
Plasma Profile after Single Dose
Administration
50 mg
100 mg
300 mg
600 mg
1000
100
10
250
200
150
100
0
1
0
12
24
36
r2=0.72
50
0
50
100
150
200
250
CSF (ng/mL)
48
Hours post dose
Plasma and CSF 1.5 hours post dose
Plasma and CSF 11 hours post dose
• Rapid absorption after oral administration
• Dose dependent pharmacokinetics
• Single doses up to 600 mg
• Multiple doses up to 250 mg bid
• Mean elimination half-life up to 9.3 hrs
Source: Stamler et al. Neurology 2019; 92 (15 Suppl.)
• CSF and free plasma levels strongly
•
correlated and within 2-fold of each other
CSF concentrations at steady state exceed
those associated with efficacy in animal
models of PD and MSA
21
bioMUSE: Natural History Study in MSA
Design
• Observational
Objectives
• Design and de-risk Phase 2
• Identify biomarker endpoints for treatment study
Population
• Early-stage MSA patients similar to Phase 2 population
• ~20 participants
Observation
Period
• 12 months
Biomarkers
Clinical Endpoints
• MRI: Iron (QSM/R2*), glial pathology (MRS), neuromelanin, regional blood flow
• Fluid: NfL protein (CSF, plasma), Aggregating α-synuclein (CSF), phos-α-synuclein (skin)
• Wearable movement sensors
• Clinical: Motor exam, autonomic function, activities of daily living, global measures of
severity and change (clinician, patient)
• Functional: Timed Up and Go, 2 min Walk Test
22
bioMUSE Natural History Study
Design and De-risk Phase 2
New MRI Template
Advanced MRI methods
Optimize Patient Selection
Assess Endpoints with Precision
Pilot Clinical Measures
Improve precision of iron
quantification by MRI
Identify “iron signature”
in early MSA vs. PD
α-synuclein in CSF
Wearable Sensors
Urinary Symptom Profile
Quantitative assessment
of motor performance
Demonstrated utility in
early MSA
Iron distribution in MSA
Fluorescence
1000000
100000
PD
10000
MSA
1000
100
Time →
Differentiation of early
MSA from PD
Sources: Presentations/Posters on file, including Claassen et al, MDS Conference 2021 and 2022.
Novel strategies for measuring
brain iron in individual regions
23
ATH434-201: Randomized Phase 2 Clinical Trial in
Early-Stage MSA
Design
• Randomized, double-blind, placebo controlled
Objectives
• Assess efficacy and safety of ATH434 in participants with MSA
• Assess target engagement based on imaging and fluid biomarkers
Population
• Early-stage MSA: ambulatory with biomarker evidence of MSA
Sample Size
• N=60 at up to 30 sites in ANZ, Europe and the U.S.
Treatment
• 12 months
• Three arms: Two dose levels of ATH434 or placebo
Primary Endpoint
• Change in iron content as measured by brain MRI
Secondary
Endpoints
• Clinical: Activities of daily living inventory (UMSARS I), motor exam, autonomic function
• Additional imaging biomarkers, fluid biomarkers (aggregating α-synuclein, NfL protein),
wearable sensor measures
24
ATH434-201 Phase 2 Design and Primary Endpoint
Iron Content (GPe)
Primary Endpoint:
Change in Brain Iron on MRI
0.30
0.25
0.20
0.15
0.10
0.05
0.00
R² = 0.63
0
20
40
60
80
Unified MSA Rating Scale
BioMUSE Natural History Study Demonstrates
Brain iron correlates with disease severity in MSA
Source: Claassen, et al. Mov Disorders 2021
25
Patient Specific “Map” to Evaluate Primary Endpoint
with Precision
ATH434 targets increased iron in
patient-specific Region of Interest
Iron Distribution
Distribution of
brain iron varies
among MSA
patients
Age
Patient Map
Patient’s age
determines the
Generates patient
specific areas with specific “map” to
increased iron
track ATH434
effect
0
Source: Data on file
Iron content [ppb]
300
26
ATH434-202: Phase 2 Biomarker Trial in MSA
Design
• Single arm, open-label
Objectives
• Assess target engagement based on imaging and fluid biomarkers
• Assess efficacy and safety of ATH434 in participants with MSA
Population
• Clinically Established (advanced) MSA with biomarker evidence of disease
Sample Size
• N=15
Treatment
• 12 months
Primary Endpoint
• Change in iron content as measured by brain MRI
Secondary
Endpoints
• Clinical: Activities of daily living inventory (UMSARS I), motor exam, autonomic function
• Additional imaging biomarkers, fluid biomarkers (aggregating α-synuclein, NfL protein)
27
Significant Commercial Opportunity in Treating
Multiple System Atrophy
Substantial Unmet Need
Strong Intent to Prescribe
Severely debilitating illnesses
with no current treatments are
ripe for new entrants targeting
underlying pathology of the
disease.
Motivated by efficacy of treating
the underlying disease and not
just the symptoms, clinicians
intend to offer ATH434 to most
of their patients with MSA.
up to
$US1.1 Billion
Potential U.S.
annual peak sales
for ATH434 in MSA
Unique MOA
Inhibition of protein aggregation
is a novel mechanism of action
that may prove to impact more
than motor symptoms.
Source: Survey of U.S. neurologists, updated 2023
Ease of Use
Twice daily oral administration of
ATH434 preferred by physicians
28
Alterity: Poised for Progress
•
•
Targeting Orphan disease with no approved
treatments
Two Phase 2 clinical trials ongoing
•
•
Double-blind trial enrolling globally
Biomarker trial enrolling in U.S.
•
bioMUSE Natural History Study de-risking Phase 2
•
Development team with multiple FDA approvals
•
Drug discovery generating patentable compounds
as next generation therapies
•
Cash balance of $16.7 M AUD as of 30 Sept 2023
Clinical Milestones
ATH434-201 Phase 2 Double-Blind Trial
Q1 2023: First Patients Dosed in U.S.
and Europe
Q2 2023: First Patient Dosed in Australia
Q3 2023: DMC recommends continuing
trial as planned
October 2023: Closed Screening
November 2023: Complete Enrollment
• Q4 2024: Study Complete
ATH434-202 Phase 2 Biomarker Trial
Q2 2023: Initiate Trial
• H1 2024: Preliminary Data
MSA Natural History Study
Q2 2023: Diagnostic Precision Data
• Q4 2023: Present new biomarker data
29
Key Milestones
Enrollment Complete
ATH434-201
Phase 2 Trial
Data with ATH434
in Monkey Model
of Parkinson’s
Disease
Study Complete
ATH434-201
Phase 2 Trial
bioMUSE
Data
Preliminary Data from
ATH434-202 Open Label
Biomarker Trial
Oct
23
Nov
23
Dec
23
Jan
24
Feb
24
Mar
24
Apr
24
May
24
Jun
24
July
24
Aug
24
Sep
24
Oct
24
Nov
24
Dec
24
Jan
25
Share your feedback
Discover